MicroRNA-17∼92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways

Hyun Yong Jin, Hiroyo Oda, Maoyi Lai, Rebecca Skalsky, Kelly Bethel, Jovan Shepherd, Seung Goo Kang, Wen Hsien Liu, Mohsen Sabouri-Ghomi, Bryan R. Cullen, Klaus Rajewsky, Changchun Xiao

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

MicroRNAs (miRNAs) have been broadly implicated in cancer, but their exact function and mechanism in carcinogenesis remain poorly understood. Elevated miR-17∼92 expression is frequently found in human cancers, mainly due to gene amplification and Myc-mediated transcriptional upregulation. Here we show that B cell-specific miR-17∼92 transgenic mice developed lymphomas with high penetrance and that, conversely, Myc-driven lymphomagenesis stringently requires two intact alleles of miR-17∼92. We experimentally identified miR-17∼92 target genes by PAR-CLIP and validated select target genes in miR-17∼92 transgenic mice. These analyses demonstrate that miR-17∼92 drives lymphomagenesis by suppressing the expression of multiple negative regulators of the PI3K and NFκB pathways and by inhibiting the mitochondrial apoptosis pathway. Accordingly, miR-17∼92-driven lymphoma cells exhibited constitutive activation of the PI3K and NFκB pathways and chemical inhibition of either pathway reduced tumour size and prolonged the survival of lymphoma-bearing mice. These findings establish miR-17∼92 as a powerful cancer driver that coordinates the activation of multiple oncogenic pathways, and demonstrate for the first time that chemical inhibition of miRNA downstream pathways has therapeutic value in treating cancers caused by miRNA dysregulation.

Original languageEnglish (US)
Pages (from-to)2377-2391
Number of pages15
JournalEMBO Journal
Volume32
Issue number17
DOIs
StatePublished - Aug 28 2013
Externally publishedYes

Fingerprint

MicroRNAs
Phosphatidylinositol 3-Kinases
Bearings (structural)
Genes
Lymphoma
Chemical activation
Neoplasms
Transgenic Mice
Tumors
Cells
Penetrance
Apoptosis
Gene Amplification
Carcinogenesis
B-Lymphocytes
Up-Regulation
Alleles
Therapeutics

Keywords

  • lymphoma
  • miR-17∼92
  • NFκB
  • PAR-CLIP
  • PI3K

ASJC Scopus subject areas

  • Molecular Biology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Neuroscience(all)
  • Medicine(all)

Cite this

MicroRNA-17∼92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways. / Jin, Hyun Yong; Oda, Hiroyo; Lai, Maoyi; Skalsky, Rebecca; Bethel, Kelly; Shepherd, Jovan; Kang, Seung Goo; Liu, Wen Hsien; Sabouri-Ghomi, Mohsen; Cullen, Bryan R.; Rajewsky, Klaus; Xiao, Changchun.

In: EMBO Journal, Vol. 32, No. 17, 28.08.2013, p. 2377-2391.

Research output: Contribution to journalArticle

Jin, HY, Oda, H, Lai, M, Skalsky, R, Bethel, K, Shepherd, J, Kang, SG, Liu, WH, Sabouri-Ghomi, M, Cullen, BR, Rajewsky, K & Xiao, C 2013, 'MicroRNA-17∼92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways', EMBO Journal, vol. 32, no. 17, pp. 2377-2391. https://doi.org/10.1038/emboj.2013.178
Jin, Hyun Yong ; Oda, Hiroyo ; Lai, Maoyi ; Skalsky, Rebecca ; Bethel, Kelly ; Shepherd, Jovan ; Kang, Seung Goo ; Liu, Wen Hsien ; Sabouri-Ghomi, Mohsen ; Cullen, Bryan R. ; Rajewsky, Klaus ; Xiao, Changchun. / MicroRNA-17∼92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways. In: EMBO Journal. 2013 ; Vol. 32, No. 17. pp. 2377-2391.
@article{57e9fd9673f74929ad74950524be2eb4,
title = "MicroRNA-17∼92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways",
abstract = "MicroRNAs (miRNAs) have been broadly implicated in cancer, but their exact function and mechanism in carcinogenesis remain poorly understood. Elevated miR-17∼92 expression is frequently found in human cancers, mainly due to gene amplification and Myc-mediated transcriptional upregulation. Here we show that B cell-specific miR-17∼92 transgenic mice developed lymphomas with high penetrance and that, conversely, Myc-driven lymphomagenesis stringently requires two intact alleles of miR-17∼92. We experimentally identified miR-17∼92 target genes by PAR-CLIP and validated select target genes in miR-17∼92 transgenic mice. These analyses demonstrate that miR-17∼92 drives lymphomagenesis by suppressing the expression of multiple negative regulators of the PI3K and NFκB pathways and by inhibiting the mitochondrial apoptosis pathway. Accordingly, miR-17∼92-driven lymphoma cells exhibited constitutive activation of the PI3K and NFκB pathways and chemical inhibition of either pathway reduced tumour size and prolonged the survival of lymphoma-bearing mice. These findings establish miR-17∼92 as a powerful cancer driver that coordinates the activation of multiple oncogenic pathways, and demonstrate for the first time that chemical inhibition of miRNA downstream pathways has therapeutic value in treating cancers caused by miRNA dysregulation.",
keywords = "lymphoma, miR-17∼92, NFκB, PAR-CLIP, PI3K",
author = "Jin, {Hyun Yong} and Hiroyo Oda and Maoyi Lai and Rebecca Skalsky and Kelly Bethel and Jovan Shepherd and Kang, {Seung Goo} and Liu, {Wen Hsien} and Mohsen Sabouri-Ghomi and Cullen, {Bryan R.} and Klaus Rajewsky and Changchun Xiao",
year = "2013",
month = "8",
day = "28",
doi = "10.1038/emboj.2013.178",
language = "English (US)",
volume = "32",
pages = "2377--2391",
journal = "EMBO Journal",
issn = "0261-4189",
publisher = "Nature Publishing Group",
number = "17",

}

TY - JOUR

T1 - MicroRNA-17∼92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways

AU - Jin, Hyun Yong

AU - Oda, Hiroyo

AU - Lai, Maoyi

AU - Skalsky, Rebecca

AU - Bethel, Kelly

AU - Shepherd, Jovan

AU - Kang, Seung Goo

AU - Liu, Wen Hsien

AU - Sabouri-Ghomi, Mohsen

AU - Cullen, Bryan R.

AU - Rajewsky, Klaus

AU - Xiao, Changchun

PY - 2013/8/28

Y1 - 2013/8/28

N2 - MicroRNAs (miRNAs) have been broadly implicated in cancer, but their exact function and mechanism in carcinogenesis remain poorly understood. Elevated miR-17∼92 expression is frequently found in human cancers, mainly due to gene amplification and Myc-mediated transcriptional upregulation. Here we show that B cell-specific miR-17∼92 transgenic mice developed lymphomas with high penetrance and that, conversely, Myc-driven lymphomagenesis stringently requires two intact alleles of miR-17∼92. We experimentally identified miR-17∼92 target genes by PAR-CLIP and validated select target genes in miR-17∼92 transgenic mice. These analyses demonstrate that miR-17∼92 drives lymphomagenesis by suppressing the expression of multiple negative regulators of the PI3K and NFκB pathways and by inhibiting the mitochondrial apoptosis pathway. Accordingly, miR-17∼92-driven lymphoma cells exhibited constitutive activation of the PI3K and NFκB pathways and chemical inhibition of either pathway reduced tumour size and prolonged the survival of lymphoma-bearing mice. These findings establish miR-17∼92 as a powerful cancer driver that coordinates the activation of multiple oncogenic pathways, and demonstrate for the first time that chemical inhibition of miRNA downstream pathways has therapeutic value in treating cancers caused by miRNA dysregulation.

AB - MicroRNAs (miRNAs) have been broadly implicated in cancer, but their exact function and mechanism in carcinogenesis remain poorly understood. Elevated miR-17∼92 expression is frequently found in human cancers, mainly due to gene amplification and Myc-mediated transcriptional upregulation. Here we show that B cell-specific miR-17∼92 transgenic mice developed lymphomas with high penetrance and that, conversely, Myc-driven lymphomagenesis stringently requires two intact alleles of miR-17∼92. We experimentally identified miR-17∼92 target genes by PAR-CLIP and validated select target genes in miR-17∼92 transgenic mice. These analyses demonstrate that miR-17∼92 drives lymphomagenesis by suppressing the expression of multiple negative regulators of the PI3K and NFκB pathways and by inhibiting the mitochondrial apoptosis pathway. Accordingly, miR-17∼92-driven lymphoma cells exhibited constitutive activation of the PI3K and NFκB pathways and chemical inhibition of either pathway reduced tumour size and prolonged the survival of lymphoma-bearing mice. These findings establish miR-17∼92 as a powerful cancer driver that coordinates the activation of multiple oncogenic pathways, and demonstrate for the first time that chemical inhibition of miRNA downstream pathways has therapeutic value in treating cancers caused by miRNA dysregulation.

KW - lymphoma

KW - miR-17∼92

KW - NFκB

KW - PAR-CLIP

KW - PI3K

UR - http://www.scopus.com/inward/record.url?scp=84883310620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883310620&partnerID=8YFLogxK

U2 - 10.1038/emboj.2013.178

DO - 10.1038/emboj.2013.178

M3 - Article

C2 - 23921550

AN - SCOPUS:84883310620

VL - 32

SP - 2377

EP - 2391

JO - EMBO Journal

JF - EMBO Journal

SN - 0261-4189

IS - 17

ER -